Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 4/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29687629 | 0.90 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL13942897 | 0.90 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL29376637 | 0.90 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL13944800 | 0.88 | KMT2A (0.51) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL421253 | 0.88 | KMT2A (0.58) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL5579212 | 0.88 | KMT2A (0.55) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL15147183 | 0.86 | KMT2A (0.49) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL15731773 | 0.86 | KMT2A (0.49) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL25446255 | 0.85 | KMT2A (0.53) | KMT2AEPHX2LMNASMN1; SMN2TLR2 | |
| SCHEMBL259018 | 0.85 | KMT2A (0.63) | KMT2AEPHX2LMNASMN1; SMN2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| EP-4399224-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | Sanofi (FR) | 2024-07-17 | — | — | EP | disclosed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | disclosed |
| WO-2023031455-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2023-03-09 | — | — | WO | disclosed |
| EP-4110800-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-01-04 | — | — | EP | disclosed |
| WO-2021175974-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | GIPR, GLP1R, GPR119 | KMT2A 4159/4885EPHX2 4305/4885LMNA 4777/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | KMT2A 4035/4885EPHX2 4399/4885LMNA 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.